Tscan Therapeutics Inc's Customers Performance

Name: Tscan Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

TCRX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


TCRX's Source of Revenues		During the corresponding time, Tscan Therapeutics Inc saw a revenue deteriorated by -65.83 % year on year, sequentially revenue grew by 7.03 %. While revenue at the Tscan Therapeutics Inc 's corporate clients • List of TCRX Customers

for the same period Tscan Therapeutics Inc revnue deteriorated by -65.83 % year on year, sequentially revenue grew by 7.03 %.

• List of TCRX Customers

Tscan Therapeutics Inc's Business Units


Reportable Segment		193.43 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Tscan Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Tscan Therapeutics Inc Contracts

Promising Results from TScan Therapeutics A New Dawn for Hematological Cancer Treatment at the ASH Annual Meeting

In an era where precision medicine continues to redefine therapeutic outcomes in oncology, TScan Therapeutics has emerged at the forefront of innovation, presenting compelling findings from its ongoing ALLOHA Phase 1 Heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. With event-free survival rates revealing a strong advantage for the treatment arm, the results signal a potential shift in the therapeutic landscape for hematological malignancies.A glance at the data from the ALLOHA trial delineates a narrative of hope and resilience within a patient population that has long faced the daunting challenges of blood cancers. With a hazard ratio (HR) of 0.30 (p=0.04), the fin...

TScan Therapeutics Secures FDAs RMAT Designation for Leading TCR-T T...

TScan Therapeutics Receives FDA s RMAT Designation for Pioneering TCR-T Therapy Candidates TSC-100 and TSC-101 A Promising Leap Forward in the Treatment of Hematologic MalignanciesTScan Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Regenerative Medicine Advanced Therapy (RMAT) designation to its two lead T-cell receptor (TCR)-engineered T cell (TCR-T) therapy candidates, TSC-100 and TSC-101. Both therapies are designed for the treatment of hematologic malignancies, specifically acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) in patients undergoing allogeneic hematopoietic cell transplantation (...

TScan Therapeutics to Present Promising Results of TSC-100 and TSC-101 in the Treatment of Heme Malignancies at Prestigious Medical Meetings and Host Virtual KOL Event for Discussion

TScan Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for cancer patients, is set to make groundbreaking strides in the treatment of heme malignancies. The company recently announced that it has been awarded the Best s Award and will be delivering an oral presentation at the upcoming Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) in 2024.The presentation will feature additional results derived from TScan Therapeutics ongoing Phase 1 study of TSC-100 and TSC-101, demonstrating the potentia...

TCRX's Stock Performance relative to it's Customers

TCRX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Tscan Therapeutics Inc	41.56	9.14	-124.31	142
SUBTOTAL	0.00	0.00	0.00	-

Sources: Tscan Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Tscan Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Tscan Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.